JAMA Cardiology
Original Investigation
February 21, 2024
Michael T.ÌýLu,ÌýMD, MPH; HeatherÌýRibaudo,ÌýPhD; BorekÌýFoldyna,ÌýMD; Markella V.ÌýZanni,ÌýMD; ThomasÌýMayrhofer,ÌýPhD; JuliaÌýKarady,ÌýMD, PhD; JanaÌýTaron,ÌýMD; Kathleen V.ÌýFitch,ÌýMSN; SaraÌýMcCallum,ÌýMPH; Tricia H.ÌýBurdo,ÌýPhD; KaylaÌýParadis,ÌýMBA; Sandeep S.ÌýHedgire,ÌýMD; Nandini M.ÌýMeyersohn,ÌýMD; ChristopherÌýDeFilippi,ÌýMD; Carlos D.ÌýMalvestutto,ÌýMD, MPH; AudraÌýSturniolo,ÌýMS; MarissaÌýDiggs,ÌýBA; SueÌýSiminski,ÌýMBA; Gerald S.ÌýBloomfield,ÌýMD; BeverlyÌýAlston-Smith,ÌýMD; PatriceÌýDesvigne-Nickens,ÌýMD; Edgar T.ÌýOverton,ÌýMD; Judith S.ÌýCurrier,ÌýMD; Judith A.ÌýAberg,ÌýMD; Carl J.ÌýFichtenbaum,ÌýMD; UdoÌýHoffmann,ÌýMD, MPH; Pamela S.ÌýDouglas,ÌýMD; Steven K.ÌýGrinspoon,ÌýMD; REPRIEVE Trial Writing Group
open access
has multimedia
JAMA Cardiol. 2024; 9(4):323-334. 10.1001/jamacardio.2023.5661
This substudy of a randomized clinical trial investigates the effects of pitavastatin on noncalcified coronary artery plaque using coronary computed tomography angiography and on inflammatory biomarkers as potential mechanisms for major adverse cardiovascular event prevention.
ÁñÁ«ÊÓƵ Network Open
Original Investigation
Cardiology
June 29, 2021
UdoÌýHoffmann,ÌýMD, MPH; Michael T.ÌýLu,ÌýMD, MPH; BorekÌýFoldyna,ÌýMD; Markella V.ÌýZanni,ÌýMD; JuliaÌýKarady,ÌýMD; JanaÌýTaron,ÌýMD; Bingxue K.ÌýZhai,ÌýMS; TriciaÌýBurdo,ÌýPhD; Kathleen V.ÌýFitch,ÌýMSN; Emma M.ÌýKileel,ÌýMPH; KennethÌýWilliams,ÌýPhD; Carl J.ÌýFichtenbaum,ÌýMD; Edgar T.ÌýOverton,ÌýMD; CarlosÌýMalvestutto,ÌýMD; JudithÌýAberg,ÌýMD; JudithÌýCurrier,ÌýMD; Craig A.ÌýSponseller,ÌýMD; KathleenÌýMelbourne,ÌýPharmD; MichelleÌýFloris-Moore,ÌýMD; CorneliusÌýVan Dam,ÌýMD; Michael C.ÌýKeefer,ÌýMD; Susan L.ÌýKoletar,ÌýMD; Pamela S.ÌýDouglas,ÌýMD; HeatherÌýRibaudo,ÌýPhD; ThomasÌýMayrhofer,ÌýPhD; Steven K.ÌýGrinspoon,ÌýMD; REPRIEVE trial
open access
ÁñÁ«ÊÓƵ Netw Open. 2021; 4(6):e2114923. 10.1001/jamanetworkopen.2021.14923
This cohort study examines the prevalence of coronary artery disease (CAD) among adults with well-controlled HIV and low to moderate risk of atherosclerotic cardiovascular disease using computed tomography angiography and assessment of inflammation and immune activation biomarkers.